A detailed history of Steward Partners Investment Advisory, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Steward Partners Investment Advisory, LLC holds 44,756 shares of VRTX stock, worth $17.8 Million. This represents 0.2% of its overall portfolio holdings.

Number of Shares
44,756
Previous 40,681 10.02%
Holding current value
$17.8 Million
Previous $19.1 Million 9.17%
% of portfolio
0.2%
Previous 0.2%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$460.0 - $505.78 $1.87 Million - $2.06 Million
4,075 Added 10.02%
44,756 $20.8 Million
Q2 2024

Aug 08, 2024

SELL
$392.81 - $485.53 $229,793 - $284,035
-585 Reduced 1.42%
40,681 $19.1 Million
Q1 2024

May 15, 2024

BUY
$407.69 - $446.08 $2.57 Million - $2.81 Million
6,299 Added 18.01%
41,266 $17.2 Million
Q4 2023

Feb 12, 2024

BUY
$343.0 - $410.68 $2.57 Million - $3.08 Million
7,504 Added 27.32%
34,967 $14.2 Million
Q3 2023

Nov 13, 2023

BUY
$338.18 - $362.46 $2.24 Million - $2.4 Million
6,619 Added 31.75%
27,463 $9.55 Million
Q2 2023

Aug 14, 2023

BUY
$314.42 - $351.91 $2.27 Million - $2.54 Million
7,209 Added 52.87%
20,844 $7.34 Million
Q1 2023

May 15, 2023

BUY
$283.23 - $323.1 $548,899 - $626,167
1,938 Added 16.57%
13,635 $4.3 Million
Q4 2022

Feb 15, 2023

BUY
$285.76 - $321.48 $1.4 Million - $1.58 Million
4,904 Added 72.19%
11,697 $3.38 Million
Q3 2022

Nov 10, 2022

SELL
$273.83 - $305.53 $27,930 - $31,164
-102 Reduced 1.48%
6,793 $1.97 Million
Q2 2022

Aug 04, 2022

SELL
$234.96 - $292.55 $97,273 - $121,115
-414 Reduced 5.66%
6,895 $1.94 Million
Q1 2022

May 02, 2022

BUY
$221.42 - $260.97 $863,095 - $1.02 Million
3,898 Added 114.28%
7,309 $1.91 Million
Q4 2021

Feb 08, 2022

SELL
$177.01 - $223.45 $49,208 - $62,119
-278 Reduced 7.54%
3,411 $749,000
Q3 2021

Nov 12, 2021

SELL
$181.39 - $202.99 $121,712 - $136,206
-671 Reduced 15.39%
3,689 $669,000
Q2 2021

Aug 13, 2021

SELL
$187.49 - $221.1 $514,285 - $606,477
-2,743 Reduced 38.62%
4,360 $879,000
Q1 2021

May 14, 2021

SELL
$207.02 - $241.31 $643,625 - $750,232
-3,109 Reduced 30.44%
7,103 $1.53 Million
Q4 2020

Feb 11, 2021

BUY
$207.01 - $276.09 $286,087 - $381,556
1,382 Added 15.65%
10,212 $2.41 Million
Q3 2020

Oct 30, 2020

SELL
$255.65 - $303.1 $139,584 - $165,492
-546 Reduced 5.82%
8,830 $2.4 Million
Q2 2020

Aug 06, 2020

BUY
$225.48 - $295.8 $1.05 Million - $1.37 Million
4,646 Added 98.22%
9,376 $2.72 Million
Q1 2020

Apr 29, 2020

BUY
$199.77 - $247.81 $70,718 - $87,724
354 Added 8.09%
4,730 $1.13 Million
Q4 2019

Jan 17, 2020

BUY
$166.71 - $223.91 $7,501 - $10,075
45 Added 1.04%
4,376 $958,000
Q3 2019

Oct 30, 2019

BUY
$166.23 - $187.09 $186,842 - $210,289
1,124 Added 35.05%
4,331 $733,000
Q2 2019

Jul 25, 2019

BUY
$164.61 - $190.37 $195,721 - $226,349
1,189 Added 58.92%
3,207 $588,000
Q1 2019

Apr 30, 2019

SELL
$163.73 - $194.7 $5,075 - $6,035
-31 Reduced 1.51%
2,018 $371,000
Q4 2018

Jan 15, 2019

BUY
$151.91 - $192.21 $21,267 - $26,909
140 Added 7.33%
2,049 $339,000
Q3 2018

Oct 23, 2018

BUY
$167.73 - $192.74 $2,180 - $2,505
13 Added 0.69%
1,909 $368,000
Q2 2018

Jul 20, 2018

SELL
$145.72 - $169.96 $10,346 - $12,067
-71 Reduced 3.61%
1,896 $322,000
Q1 2018

Apr 20, 2018

BUY
$151.6 - $177.13 $35,474 - $41,448
234 Added 13.5%
1,967 $320,000
Q4 2017

Jan 19, 2018

BUY
$137.28 - $155.55 $28,966 - $32,821
211 Added 13.86%
1,733 $259,000
Q3 2017

Nov 22, 2017

BUY
$148.13 - $162.24 $29,774 - $32,610
201 Added 15.22%
1,522 $231,000
Q2 2017

Nov 22, 2017

BUY
N/A
118 Added 9.81%
1,321 $170,000
Q1 2017

Nov 22, 2017

BUY
N/A
1,203
1,203 $131,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $102B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Steward Partners Investment Advisory, LLC Portfolio

Follow Steward Partners Investment Advisory, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Steward Partners Investment Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Steward Partners Investment Advisory, LLC with notifications on news.